Open Orphan #ORPH – Major year-on-year revenue growth and profitable H1 2021 performance following a year of turnaround and transition in 2020 September 20, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2021. These results show a continued pattern of profitability from Q4 2020 to a firmly profitable position delivering a positive EBITDA profit of £2.1 million compared to an EBITDA loss of £4.1 million in H1 2020. We…

Open Orphan (ORPH) Final Results to 31 December 2020 June 17, 2021 – Posted in: Blog, Open Orphan (ORPH)

Final Results to 31 December 2020 Important year of transition following the various merger and acquisition activities in 2019 and January 2020 Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its audited results for the 12 months to 31 December 2020. Following the acquisition of hVIVO in January of last year, 2020 was a…

Open Orphan PLC #ORPH – Result of General Meeting April 29, 2021 – Posted in: Blog, Open Orphan (ORPH)

Result of General Meeting Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , announces that all resolutions proposed at the General Meeting held earlier today were duly passed. Further announcements regarding the proposed Distribution in Specie will be made in due course. For further information, please contact: Open Orphan plc www.openorphan.com Cathal Friel, Executive Chairman +353 (0)…

Open Orphan PLC #ORPH – Holding(s) in Company January 29, 2021 – Posted in: Uncategorized

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Open Orphan Plc Queen Mary BioEnterprises Innovation Centre 42 New Road London E1 2AX 1b. Please indicate if the issuer is a non-UK issuer (please mark with…

Open Orphan – Result of General Meeting June 11, 2020 – Posted in: Open Orphan (ORPH)

Thursday 11th June, 2020 Open Orphan plc (“Open Orphan”, or the “Company”) Result of General Meeting Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that at the Company’s General Meeting held earlier today in relation to the Fundraising, all of the Resolutions put to the meeting were duly passed. The Conditional…

Open Orphan #ORPH – Major New Contract Win for Venn Life Sciences – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH) a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that it has signed a major contract with a leading vaccine developer and one of the top pharmaceutical companies in the world. The contract with Venn Life Sciences, which is part of Open Orphan, builds on earlier successful contracts between the companies…

Open Orphan plc – Launch of Covid-19 Antibody Testing June 4, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (“Open Orphan” or the “Company”) Launch of Covid-19 Antibody Testing Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, announces the launch of hVIVO COVID Clear Test, the Company’s antibody testing service, following the successful completion of installation, testing and training. The antibody tests, which utilise the Quotient MosaiQ™ system and…

Alan Green CEO of Brand Communications talks about: i3 Energy #I3E Cranswick #CWK Tertiary Minerals #TYM Open Orphan #ORPH November 26, 2019 – Posted in: Blog, Open Orphan (ORPH)

(Interview starts at 12 minutes 20 seconds)

Open Orphan CCO Maurice Treacy discusses the early adopters of ORPH’s Genomic Health DataBANK platform on the Vox Markets Podcast – Posted in: Open Orphan (ORPH)

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services businesses. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform, enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in…

Open Orphan (ORPH) – Results of AGM October 2, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that all the resolutions put to shareholders at the Annual General Meeting of the Company held earlier today were duly passed. Enquiries: Open Orphan plc Tel: +353 1 644 0007 Cathal Friel, Chief Executive Officer Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900 John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363 Anthony Farrell…